Provided are crystalline forms of (R)-1-(tert-butyl)-N-(8-(2-((1-methyl-1H-pyrazol-4-yl)amino)pyrimidin-4-yl)-2-(oxetan-3-yl)-2,3,4,5-tetrahydro-1H-benzo[c]azepin-5-yl)-1H-1,2,3-triazole-4-carboxamide, pharmaceutical compositions, methods of use and methods of making thereof.L'invention concerne des formes cristallines de (R)-1-(tert-butyl)-N-(8-(2-((1-méthyl-1H-pyrazol-4-yl) amino) pyrimidin-4-yl)-2-(oxétan-3-yl))-2,3,4,5-tétrahydro-1H-benzo[c]azépin-5-yl)-1H-1,2,3-triazole-4-carboxamide, des compositions pharmaceutiques, des procédés d'utilisation et des procédés de production de ceux-ci.
